APA (7th ed.) Citation

Groen, K., Seefat, M. R., Holt, B. v. d., Schjesvold, F. H., Stege, C. A., Levin, M., . . . Zweegman, S. (2022). P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13. HemaSphere, 6, 796-797. https://doi.org/10.1097/01.HS9.0000846492.51234.76

Chicago Style (17th ed.) Citation

Groen, K., et al. "P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13." HemaSphere 6 (2022): 796-797. https://doi.org/10.1097/01.HS9.0000846492.51234.76.

MLA (8th ed.) Citation

Groen, K., et al. "P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13." HemaSphere, vol. 6, 2022, pp. 796-797, https://doi.org/10.1097/01.HS9.0000846492.51234.76.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.